FibroGen (FGEN) Revenue & Revenue Breakdown

Overview ForecastOwnership Financials Chart Transcripts

FibroGen Revenue Highlights

Latest Revenue (Y)

$6.44M

Latest Revenue (Q)

$1.08M

Main Segment (Y)

Drug Product Revenue

Main Geography (Y)

Europe

FibroGen Revenue by Period

FibroGen Revenue by Year

Date	Revenue	Change
2025-12-31	$6.44M	-78.26%
2024-12-31	$29.62M	-36.71%
2023-12-31	$46.80M	-66.74%
2022-12-31	$140.73M	-40.19%
2021-12-31	$235.31M	33.46%
2020-12-31	$176.32M	-31.28%
2019-12-31	$256.58M	20.48%
2018-12-31	$212.96M	69.46%
2017-12-31	$125.67M	-30.02%
2016-12-31	$179.58M	-0.69%
2015-12-31	$180.83M	31.41%
2014-12-31	$137.60M	34.68%
2013-12-31	$102.17M	54.96%
2012-12-31	$65.93M	-

FibroGen generated $6.44M in revenue during NA 2025, up -78.26% compared to the previous quarter, and up 3.65% compared to the same period a year ago.

FibroGen Revenue by Quarter

Date	Revenue	Change
2025-09-30	$1.08M	-20.18%
2025-06-30	$1.35M	-50.78%
2025-03-31	$2.74M	-102.22%
2024-12-31	$-123.26M	-366.02%
2024-09-30	$46.33M	-8.51%
2024-06-30	$50.64M	99.66%
2024-03-31	$25.36M	-6.54%
2023-12-31	$27.14M	-32.38%
2023-09-30	$40.13M	-9.44%
2023-06-30	$44.32M	22.56%
2023-03-31	$36.16M	5.22%
2022-12-31	$34.37M	118.41%
2022-09-30	$15.73M	-47.21%
2022-06-30	$29.81M	-51.00%
2022-03-31	$60.83M	267.69%
2021-12-31	$16.54M	-89.39%
2021-09-30	$155.97M	540.18%
2021-06-30	$24.36M	-36.60%
2021-03-31	$38.43M	-40.88%
2020-12-31	$65.00M	47.62%
2020-09-30	$44.03M	2.67%
2020-06-30	$42.89M	75.76%
2020-03-31	$24.40M	206.01%
2019-12-31	$7.97M	-75.96%
2019-09-30	$33.17M	-82.68%
2019-06-30	$191.57M	702.77%
2019-03-31	$23.86M	-77.92%
2018-12-31	$108.05M	272.25%
2018-09-30	$29.03M	-33.96%
2018-06-30	$43.95M	37.67%
2018-03-31	$31.93M	-24.90%
2017-12-31	$42.51M	55.87%
2017-09-30	$27.27M	-5.95%
2017-06-30	$29.00M	7.83%
2017-03-31	$26.89M	-15.73%
2016-12-31	$31.91M	6.01%
2016-09-30	$30.10M	-66.28%
2016-06-30	$89.28M	215.68%
2016-03-31	$28.28M	15.71%
2015-12-31	$24.44M	25.10%
2015-09-30	$19.54M	-83.79%
2015-06-30	$120.55M	639.66%
2015-03-31	$16.30M	1.20%
2014-12-31	$16.11M	17.88%
2014-09-30	$13.66M	-84.81%
2014-06-30	$89.96M	403.23%
2014-03-31	$17.88M	44.28%
2013-12-31	$12.39M	-82.61%
2013-09-30	$71.25M	-

FibroGen generated $1.08M in revenue during Q3 2025, up -20.18% compared to the previous quarter, and up 2.12% compared to the same period a year ago.

FibroGen Revenue Breakdown

FibroGen Revenue Breakdown by Product

Annual Revenue by Product

Product/Service	Dec 25	Dec 24	Dec 23	Dec 22	Dec 21
Drug Product Revenue	$5.85M	$27.67M	$18.75M	$11.09M	$962.00K

FibroGen's latest annual revenue breakdown by segment (product or service), as of Dec 25: Drug Product Revenue (100.00%).

Quarterly Revenue by Product

Product/Service	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Mar 21	Dec 20	Sep 20	Jun 20
Drug Product Revenue	$1.08M	$957.00K	$1.22M	$2.60M	$3.45M	$-262.00K	$24.49M	$1.05M	$1.32M	$14.27M	$2.11M	$6.48M	$1.09M	$7.59M	$1.13M	$8.48M	$686.00K	$8.24M	-	-
Product	-	-	-	-	-	$46.21M	$30.54M	$29.39M	$35.92M	$27.90M	$19.83M	-	-	-	-	-	-	-	-	-
License	-	-	-	-	-	-	-	$2.65M	-	-	-	-	-	-	-	-	-	-	-	-
Royalty	-	-	-	-	-	-	-	-	-	-	-	-	$200.00K	-	-	-	-	-	-	-

FibroGen's latest quarterly revenue breakdown by segment (product or service), as of Dec 25: Drug Product Revenue (100.00%).

FibroGen Revenue Breakdown by Country

Annual Revenue by Country

Country	Dec 25	Dec 24	Dec 23	Dec 22	Dec 21
JAPAN	$797.00K	$-2.85M	$15.87M	$9.76M	$2.31M
Europe	$5.64M	$6.27M	$9.55M	$33.82M	$131.24M
UNITED STATES	-	$26.11M	$12.96M	$12.52M	$46.12M
CHINA	-	$91.00K	$109.38M	$84.63M	$55.64M
All Other	-	-	-	-	-

FibroGen's latest annual revenue breakdown by geography, as of Dec 25: Europe (87.62%), and JAPAN (12.38%).

Quarterly Revenue by Country

Country	Dec 24	Sep 24	Mar 24	Dec 23	Jun 23	Mar 23
CHINA	-	$4.50M	$2.10M	$104.38M	$4.70M	$300.00K

FibroGen Peer Comparison by Revenue

Ticker	Company	Last Year Revenue	Last Quarter Revenue
MRSN	Mersana Therapeutics	$40.50M	$11.01M
XFOR	X4 Pharmaceuticals	$35.11M	$1.76M
CELU	Celularity	$22.77M	$5.28M
FGEN	FibroGen	$6.44M	$1.08M
XLO	Xilio Therapeutics	$6.34M	$19.07M
OKUR	OnKure Therapeutics	-	-
PDSB	PDS Bio	-	-
KZR	Kezar Life Sciences	-	-
ALGS	Aligos Therapeutics	-	$965.00K
TPST	Tempest Therapeutics	-	-

FGEN Revenue FAQ

What is FibroGen’s yearly revenue?

FibroGen's yearly revenue for 2025 was $6.44M, representing a decrease of -78.26% compared to 2024. The company's yearly revenue for 2024 was $29.62M, representing a decrease of -36.71% compared to 2023. FGEN's yearly revenue for 2023 was $46.8M, representing a decrease of -66.74% compared to 2022.

What is FibroGen’s quarterly revenue?

FibroGen's quarterly revenue for Q3 2025 was $1.08M, a -20.18% decrease from the previous quarter (Q2 2025), and a -97.68% decrease year-over-year (Q3 2024). The company's quarterly revenue for Q2 2025 was $1.35M, a -50.78% decrease from the previous quarter (Q1 2025), and a -97.34% decrease year-over-year (Q2 2024). FGEN's quarterly revenue for Q1 2025 was $2.74M, a -102.22% decrease from the previous quarter (Q4 2024), and a -89.20% decrease year-over-year (Q1 2024).

What is FibroGen’s revenue growth rate?

FibroGen's revenue growth rate for the last 3 years (2023-2025) was -86.24%, and for the last 5 years (2021-2025) was -97.26%.

What are FibroGen’s revenue streams?

FibroGen's revenue streams in c 25 are Drug Product Revenue

What is FibroGen’s main source of revenue?

For the fiscal year ending Dec 25, the largest source of revenue of FibroGen was Drug Product Revenue. This segment made a revenue of $5.85M, representing 100.00% of the company's total revenue.